ArticleThe Canadian journal of urology2026
Treatment of interstitial cystitis with intravesical instillation of recombinant human collagen type Ⅲ.
Article in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial cystitis (IC) is a chronic condition characterized by frequent urination, urgency, and pelvic pain. While its pathogenesis remains incompletely understood, the prevailing epithelial theory suggests that a defective glycosaminoglycan (GAG) layer increases bladder permeability, allowing urinary toxins to chronically stimulate the detrusor muscle and activate mast cells. Current therapies, such as intravesical hyaluronic acid instillation, have demonstrated limited efficacy. This study aimed to evaluate the feasibility of sterile recombinant human collagen type III (rHCIII) in mitigating bladder injury and its histological effects on urothelial integrity.
methodAn IC rat model was established using protamine sulfate and lipopolysaccharide. The model was subsequently treated with sterile rHCⅢ via bladder instillation. Bladder tissues were analyzed using Hematoxylin-eosin (H&E) staining for general histopathology, Masson and van Gieson staining for collagen fiber organization, and Toluidine blue (TB) staining for mast cell infiltration. Apoptosis was assessed by Terminal Deoxynucleotidyl Transferase mediated dUTP Nick-End Labeling (TUNEL) staining and immunohistochemistry for Caspase-3. The localization of the perfused rHCⅢ was tracked using immunohistochemistry for a 6×Histidine (HIS) tag.
resultImmunohistochemistry confirmed the presence of rHCⅢ in the bladder mucosal and submucosal layers. Treatment with rHCⅢ significantly reduced bladder cell apoptosis compared to the IC group (p < 0.001). Furthermore, the collagen fibers in the submucosal and muscular layers demonstrated a more compact and organized arrangement post-treatment. Mast cell infiltration was also markedly diminished following rHCⅢ instillation (p < 0.001).
conclusionIntravesical instillation of sterile rHCⅢ mitigates apoptosis of mucosal epithelial cells and reinforces the submucosal collagen structure. This intervention promotes a more organized tissue architecture, which may help maintain urothelial structural integrity. These findings provide preclinical evidence supporting the repair-oriented potential of rHCⅢ instillation for interstitial cystitis.
Indexed as
Identifiers
42682051What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.